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Purpose: The management of hyperglycemia is
challenging in older patients with type 2 diabetes
owing to excess fragility and risk for adverse
outcomes should hypoglycemia episodes occur. We
evaluated baseline β-cell function as a potential risk
factor for the development of hypoglycemia when
saxagliptin or glimepiride was added in patients aged
Z65 years whose type 2 diabetes was poorly
controlled on stable metformin monotherapy.
Methods: A post hoc analysis of data from the
GENERATION (Efﬁcacy and Tolerability of Saxaglip-
tin Compared with Glimepiride in Elderly Patients with
Type 2 Diabetes: A Randomized, Controlled Study)
trial, which enrolled 720 patients agedZ65 years, was
conducted. β-Cell function was assessed using homeo-
stasis model assessment-2%β (HOMA-2%β).
Findings: The percentage of patients experiencing
any hypoglycemia event (ie, symptomatic event or event
of plasma glucose concentration o54 mg/dL regardless
of symptoms) was lower with saxagliptin compared
with glimepiride (5.8% vs 34.8%). Regardless of
treatment, patients with lower (median HOMA-2%β
r39.1% [rmedian]) versus higher (HOMA-2%β
above median value [4median]) baseline β-cell function
had a higher hypoglycemia event rate (1.27 vs 0.82
events/patient-year; adjusted incidence rate ratio
[IRR] ¼ 1.800; 95% CI, 1.501–2.159). In patients
receiving glimepiride, the hypoglycemia event rate was
higher in patients with baseline HOMA-2%βrmedian
versus 4median (2.29 vs 1.60 events/patient-year;
adjusted IRR ¼ 1.737; 95% CI, 1.439–2.097); corre-
sponding saxagliptin hypoglycemia event rates were too
low to draw meaningful conclusions (0.16 vs 0.09
events/patient-year; adjusted IRR ¼ 2.457; 95% CI,] 20161.148–5.256). The association between lower β-cell
function at baseline and increased prevalence of hypo-
glycemia was particularly strong in patients aged Z75
years (adjusted IRR ¼ 2.409; 95% CI, 1.686–3.442;
P o 0.001), although it was also signiﬁcant in patients
aged 65 to o75 years old (adjusted IRR, 1.654; 95%
CI, 1.339–2.043; P o 0.001).
Implications: In patients with lower β-cell function,
the addition of a sulfonylurea to a metformin regimen
was associated with an increased risk for hypoglycemia
compared with that in patients with higher β-cell
function; low hypoglycemia event rates with the addi-
tion of saxagliptin limited equivalent assessments. These
ﬁndings in older patients are especially relevant because
morbidity associated with hypoglycemia is higher in this
age group. ClinicalTrials.gov identiﬁer: NCT01006603
(ClinicalTrials.gov) (Clin Ther. 2016;]:]]]–]]]) & 2016
The Authors. Published by Elsevier HS Journals, Inc.
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gliptin.INTRODUCTION
The global prevalence of diabetes was 382 million in
2013 and is projected to increase to 592 million by
2035.1 The burden of diabetes is increasing globally
and is expected to be greatest among patients aged1
Clinical Therapeutics60 to 79.1 Similar to the management of diabetes in the
young, glycemic treatment goals in older (Z65 years)
patients should be individualized.2 Special consi-
derations for the care of older patients with diabetes
include shared decision making, functional and
cognitive status, coexisting illness, and life
expectancy.2 A major concern in the management of
older patients with type 2 diabetes (T2D) is
hypoglycemia. Compared with younger (o60 years)
patients, hypoglycemia occurs more frequently in older
patients (Z70 years) with T2D even after adjustment
for sex, glucose control, and comorbid conditions.3
Additionally, a greater frequency of asymptomatic
hypoglycemia,3 impaired hypoglycemia awareness,
and prolongation of hypoglycemia-induced reaction
times to auditory stimulation have been observed in
adults aged Z65 years,4 further compounding and
contributing to management difﬁculties.
Hypoglycemia is associated with poor clinical out-
comes and increased mortality in older adults. In older
patients with T2D, hypoglycemia increases the risk for
falls,5 fall-related injuries,6,7 dementia,8 hospitalization,
and the need for long-term care.6 Furthermore, older
adults who are hospitalized for hypoglycemia are at
increased risk for recurrent hypoglycemia, subsequent
hospitalization, and mortality.9 Therefore, minimizing
the risk for hypoglycemia in older adults with T2D is of
utmost importance, and antidiabetes medications
should be selected accordingly.
Saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhib-
itor,10,11 has demonstrated efﬁcacy and tolerability in
retrospective analyses in adults aged Z65 year with
T2D, when used as monotherapy or add-on therapy and
is associated with a low risk for hypoglycemia.12–14 In a
multinational, randomized, double-blind clinical trial
enrolling patients aged Z65 years with T2D and
inadequate glycemic control on metformin
(N = 720), a similar percentage of patients in the
saxagliptin and glimepiride groups achieved glycosylated
hemoglobin (HbA1c) o7% after 52 weeks of treatment,
without conﬁrmed or severe hypoglycemia (GENERA-
TION [Efﬁcacy and Tolerability of Saxagliptin
Compared with Glimepiride in Elderly Patients with
Type 2 Diabetes: A Randomized, Controlled Study];
NCT01006603).15 Saxagliptin was generally well
tolerated, and the prevalence of any hypoglycemia
event was lower with saxagliptin compared with
glimepiride. An understanding of the factors that
contribute to hypoglycemia in older individuals with2T2D is important in optimizing treatment. Therefore, we
conducted a post hoc analysis of the GENERATION
study to evaluate baseline β-cell function as a potential
risk factor for the development of hypoglycemia in older
patients whose T2D was poorly controlled on stable
metformin monotherapy and who received add-on ther-
apy with saxagliptin or glimepiride.MATERIALS AND METHODS
Study Design
This was a post hoc analysis of the 52-week
GENERATION trial, the full details of which have
been previously published.15 Brieﬂy, after a 2-week
patient-blinded, placebo lead-in period, patients aged
Z65 years were randomized 1:1 to receive double-
blind saxagliptin 5 mg/d plus placebo or glimepiride
1 mg/d plus placebo, added to metformin for 52 weeks
(12-week titration period plus 40-week maintenance
period). Randomization was stratiﬁed by age to achieve
60% of patients aged 65 to o75 years and 40%
of patients aged Z75 years. During the ﬁrst 12 weeks,
glimepiride or placebo could be increased in 1- or
2-mg/d increments up to 6 mg/d to attain fasting
plasma glucose (FPG) r110 mg/dL. Thereafter, glime-
piride or placebo could not be increased but could be
decreased if hypoglycemia occurred.
Patients
Eligible patients were aged Z65 years, had T2D
and HbA1c 7.0% to 9.0% at screening, and had been
on stable metformin at any dose for Z8 weeks
before enrollment. Exclusion criteria included type
1 diabetes (T1D), history of ketoacidosis or hyper-
osmolar nonketotic coma, renal impairment (creati-
nine clearanceo60 mL/min), end-stage renal disease
on hemodialysis, or receiving any antidiabetes med-
ications other than metformin within 8 weeks of
enrollment. In this post hoc analysis, only patients
with baseline β-cell function data, as assessed by
homeostatic model assessment-2%β (HOMA-
2%β),16,17 were included (Figure 1).
End Points
The prespeciﬁed primary efﬁcacy end point, the
percentage of patients achieving HbA1c o7.0% at
week 52 without conﬁrmed or severe hypoglycemia,
has been previously published.15 In this post hoc
report, the primary end point was analyzed inVolume ] Number ]
720  randomized 
360 randomized to
saxagliptin + metformin 
289 (80.3%) completed
52 weeks of treatment  
71 (19.7%)  discontinued: 
Voluntary discontinuation: 17 
Safety reasons: 1 
Noncompliance: 1 
Study-specific criteria: 33 
Adverse event: 15 
Death: 1 
Other: 3 
285 (79.2%) completed
52 weeks of treatment  
272 with HOMA-2%β
assessment
279 with HOMA-2%β
assessment
360 randomized to
glimepiride + metformin 
75 (20.8%)  discontinued: 
Voluntary discontinuation: 19 
Safety reasons: 1 
Noncompliance: 3 
Incorrect enrollment: 2 
Lost to follow-up: 1 
Study-specific criteria: 34 
Adverse event: 7 
Death: 1 
Other: 7 
359 analyzed
for primary end point  
359 analyzed
for primary end point
Figure 1. Disposition of randomized patients. HOMA-2%β ¼ homeostasis model assessment-2%β.
S. Perl et al.subgroups of patients stratiﬁed by HOMA-2%β.
Conﬁrmed hypoglycemia was deﬁned as a
symptomatic or asymptomatic event with plasma
glucose o54 mg/dL that required no external
assistance, and severe hypoglycemia was deﬁned as a
symptomatic event requiring external assistance owing
to severe impairment in consciousness or behavior,
with or without plasma glucose concentration o54
mg/dL, but with prompt recovery after glucose
or glucagon administration. For the evaluation of
baseline β-cell function as a risk factor for hypoglyce-
mia, hypoglycemia was deﬁned as any hypoglycemia
event, including any reported symptomatic event or
event of plasma glucose concentration o54 mg/dL,
regardless of symptoms.
Statistical Analysis
Efﬁcacy analyses were performed using a logistic
regression. The main efﬁcacy analysis model included
response of HbA1c o7.0% without conﬁrmed or severe] 2016hypoglycemia at week 52 as the dependent variable, and
treatment, age category (Z75 oro75 years), and baseline
HbA1c as the factors.
15 The HOMA-2%β subgroup
efﬁcacy analysis model included response of HbA1c
o7.0% without conﬁrmed or severe hypoglycemia at
week 52 as the dependent variable, and treatment, age
category (Z75 or o75 years), baseline HOMA-2%β
category (at or below the median [rmedian] or above the
median [˃median], as calculated from all patients with
baseline HOMA-2%β data, regardless of treatment), and
treatment by baseline HOMA-2%β category interaction
as the factors.
Poisson regressions were conducted for analyzing
hypoglycemia incidence rate ratios (IRRs). For example,
for analysis of hypoglycemia risk for HOMA-2%β or age
by treatment, the model included the number of hypo-
glycemia events during the treatment period as the
dependent variable, baseline HOMA-2%β category
(r or 4median) or age category (Z75 or o75 years)
as the factor, and baseline HbA1c as the covariate,3
Clinical Therapeuticsanalyzed by treatment group (saxagliptin plus metformin
and glimepiride plus metformin) separately.RESULTS
Of the 720 randomized patients, 289 (80.3%) in the
saxagliptin group and 285 (79.2%) in the glimepiride
group completed the 52-week treatment period
(Figure 1).15 None of the patients in the saxagliptin
group and 7 patients in the glimepiride group
discontinued from the study because of severe or
frequent hypoglycemia events. Baseline demographic
and disease characteristics were generally balanced
across treatment groups and were representative of
older individuals with T2D. However, patients with
baseline HOMA-2%β rmedian (median, 39.1%)
had higher mean HbA1c and FPG values and lower
fasting insulin values at baseline compared with those
in patients with baseline HOMA-2%β 4median
(Table).
As previously reported, a similar percentage of
patients achieved HbA1c o7.0% at week 52 without
conﬁrmed or severe hypoglycemia (prespeciﬁed primary
end point) in the saxagliptin (37.9%) and glimepiride
(38.2%) groups.15 However, a signiﬁcantly greater
percentage of patients experienced a conﬁrmed or
severe hypoglycemia event in the glimepiride group
(15.3%) compared with the saxagliptin group (1.1%)
(P o 0.0001).15 Moreover, in the glimepiride group, a
greater percentage of aged patients o75 years reported
Z1 conﬁrmed or severe hypoglycemia event (18.5%)
compared with patients agedZ75 years (10.5%). In the
saxagliptin group, a similar percentage of patients
reported Z1 conﬁrmed or severe hypoglycemia
event in the 2 age groups (0.9% and 1.4%,
respectively). In the present analysis, while similar
between treatment groups, the percentage of patients
who achieved HbA1c o7.0% at week 52 without
severe or conﬁrmed hypoglycemia was higher in
patients with a HOMA-2%β 4median (saxagliptin,
42.9%; glimepiride, 44.4%) than in patients with
HOMA-2%β rmedian (saxagliptin, 36.4%;
glimepiride, 34.0%) (Figure 2).
For the evaluation of baseline β-cell function as a
risk factor for hypoglycemia, the broader deﬁnition of
hypoglycemia (which included any reported sympto-
matic event and symptomatic or asymptomatic events
of plasma glucose concentration o54 mg/dL) was
used. Using this deﬁnition of hypoglycemia, the4percentages of patients who experienced Z1 hypo-
glycemia event were 5.8% in the saxagliptin group
and 34.8% in the glimepiride group. Regardless of
treatment, patients with baseline HOMA-2%βrmedian
had a higher hypoglycemia event rate (1.27 events/
patient-year) compared with that in patients with base-
line HOMA-2%β 4median (0.82 events/patient-year)
(adjusted IRR, 1.800; 95% CI, 1.501–2.159).
In the glimepiride group, patients with baseline
HOMA-2%β rmedian had a higher hypoglycemia
event rate (2.29 events/patient-year) compared with
that in patients with baseline HOMA-2%β 4median
(1.60 events/patient-year) (adjusted IRR, 1.737; 95%
CI, 1.439–2.097) (Figure 3). In the saxagliptin group,
hypoglycemia event rates were much lower (0.16
events/patient-year in patients with a baseline
HOMA-2%β rmedian compared with 0.09 events/
patient-year in patients with a baseline HOMA-2%
β 4median; adjusted IRR, 2.457; 95% CI, 1.148–
5.256) (Figure 3).
Overall, patients aged Z75 years had a lower
hypoglycemia event rate compared with that in pa-
tients aged o75 years (0.74 vs 1.28 events/patient-
year; adjusted IRR, 0.585; 95% CI, 0.494–0.692). In
the glimepiride group, patients aged Z75 years had a
lower hypoglycemia event rate (1.37 events/patient-
year) compared with that in patients aged o75 years
(2.44 events/patient-year) (adjusted IRR, 0.556; 95%
CI, 0.466–0.663) (Figure 4). In the saxagliptin group,
hypoglycemia event rates were much lower and varied
less by age, with 0.15 events/patient-year in patients
aged Z75 years compared with 0.11 events/patient
year in patients aged o75 years (adjusted IRR,
1.397; 95% CI, 0.751–2.598) (Figure 4). Regardless
of treatment, the association between baseline
HOMA-2%β rmedian and increased prevalence of
hypoglycemia was particularly strong in patients
aged Z75 years (adjusted IRR, 2.409; 95% CI,
1.686–3.442; P o 0.001) (Figure 5). Baseline
HOMA-2%β rmedian was also associated with an
increased prevalence of hypoglycemia in patients aged
o75 years (adjusted IRR, 1.654; 95% CI, 1.339–
2.043; P o 0.001) (Figure 5).DISCUSSION
T2D is a chronic, progressive disease18 characterized
by reduced tissue sensitivity to insulin and impaired
insulin secretion.19 Pancreatic β-cell dysfunction is anVolume ] Number ]
Table. Patients’ baseline demographic and clinical characteristics. HOMA-2%β. Data are given as mean (SD)
unless otherwise noted.
Characteristic
Saxagliptin þ Metformin Glimepiride þ Metformin All Patients
rMedian
HOMA-2%β
(n ¼ 132)
4Median
HOMA-2%β
(n ¼ 140)
rMedian
HOMA-2%β
(n ¼ 144)
4Median
HOMA-2%β
(n ¼ 135)
rMedian
HOMA-2%β
(n ¼ 276)
4Median
HOMA-2%β
(n ¼ 275)
Demographic
Men, no. (%) 84 (64) 79 (56) 92 (64) 77 (57) 176 (64) 156 (57)
Age, y
Mean (SD), y 73 (6) 71 (5) 73 (5) 72 (5) 73 (6) 72 (5)
Category, no. (%)
o75 y 79 (60) 99 (71) 88 (61) 84 (62) 167 (61) 183 (66)
Z75 y 53 (40) 41 (29) 56 (39) 51 (38) 109 (40) 92 (34)
Race, no. (%)
White 129 (98) 139 (99) 143 (99) 132 (98) 272 (99) 271 (99)
Black 0 1 (0.7) 0 0 0 1 (0.4)
Asian 0 0 0 1 (0.7) 0 1 (0.4)
Other 3 (2) 0 1 (0.7) 2 (2) 4 (1) 2 (0.7)
Clinical
BMI, kg/m2 29 (4) 31 (5) 29 (4) 31 (5) 29 (4) 31 (5)
Duration of T2D, y 8 (5) 6 (6) 8 (6) 7 (6) 8 (6) 7 (6)
HbA1c
Mean (SD), % 7.7 (0.7) 7.4 (0.6) 7.8 (0.7) 7.4 (0.5) 7.8 (0.7) 7.4 (0.5)
Category, no. (%)
o7% 7 (5) 24 (17) 10 (7) 29 (22) 17 (6) 53 (19)
7% to o8% 87 (66) 98 (70) 86 (60) 88 (65) 173 (63) 186 (68)
8% to o9% 27 (21) 16 (11) 38 (26) 18 (13) 65 (24) 34 (12)
Z9% 11 (8) 2 (1) 10 (7) 0 21 (8) 2 (0.7)
FPG, mg/dL 173 (37) 148 (24) 179 (40) 147 (23) 176 (39) 147 (24)
Fasting insulin,
mU/mL
8 (4) 17 (10) 8 (4) 16 (7) 8 (4) 17 (9)
Prior metformin
dose, mg
1704 (629) 1541 (759) 1694 (635) 1438 (655) 1699 (631) 1491 (710)
BM I ¼body mass index; FPG ¼ fasting plasma glucose; HbA1c ¼ glycosylated hemoglobin; HOMA-2%β ¼ homeostasis
model assessment-2%β; T2D ¼ type 2 diabetes.
S. Perl et al.early event in the course of T2D and progressively
worsens over time.20–22 Glycemic variability and
glycemic control are related to β-cell function.23,24
Therefore, understanding the relationship between
baseline β-cell function as a risk factor for hypoglyce-
mia is useful, especially in individuals at high risk
for hypoglycemia and susceptible to the complications
of hypoglycemia, such as older patients. The ﬁndings
from this analysis showed that, regardless of] 2016treatment, lower baseline β-cell function, assessed
using HOMA-2%β, was associated with a higher
hypoglycemia event rate in older patients. Moreover,
the association between lower β-cell function at base-
line and increased prevalence of hypoglycemia was
particularly strong in patients aged Z75 years.
The effect of β-cell function on hypoglycemia risk was
not directly assessed in this post hoc analysis, and hence,
a causal relationship between low β-cell function and5
ORb
1010.1
All Patients
HOMA-2%β ≤mediana
HOMA-2%β >mediana
136/359 (37.9)
Saxagliptin Plus Metformin
N = 359
48/132 (36.4)
60/140 (42.9)
137/359 (38.2)
Glimepiride Plus Metformin
N = 359
49/144 (34.0)
0.95 (0.70, 1.30)
1.11 (0.67, 1.81)
0.97 (0.60, 1.58) 60/135 (44.4)
Figure 2. Percentages of patients with HbA1c o7% without confirmed or severe hypoglycemia (primary
efficacy end point) at week 52 of treatment with saxagliptin plus metformin or glimepiride plus
metformin. aData are given as the percentage of responders/number of patients with nonmissing
HOMA-2%β data. bOdds ratio relative to glimepiride plus metformin; median (SD) HOMA-2%β:
39.1% (26.1%). The main efficacy analysis model included response of HbA1c o7% without
confirmed or severe hypoglycemia at week 52 as the dependent variable, treatment, age category
(Z75 or o75 years), baseline HbA1c and treatment by baseline HbA1c interaction as the factors.
The HOMA-2%β subgroup efficacy analysis model included response of HbA1c o7.0% without
confirmed or severe hypoglycemia at week 52 as the dependent variable and treatment, age
category (Z75 or o75 years), baseline HOMA-2%β category (rmedian, 4median), and
treatment by baseline HOMA-2%β category interaction as the factors. HbA1c ¼ glycosylated
hemoglobin; HOMA-2%β ¼ homeostasis model assessment-2%β; OR ¼ odds ratio.
Clinical Therapeuticshypoglycemia risk has not been established. However, it
is of interest to consider how β-cell function and
hypoglycemia risk may possibly be related. A potentialHypoglycemia event ratea
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Figure 4. Hypoglycemia events based on age in the saxagliptin and glimepiride treatment groups. aEvent rate:
number of hypoglycemia events per total exposure patient-years. bAdjusted IRR: Z75 years/o75
years (95% CI), performed using Poisson regression with number of hypoglycemia events during
treatment period as the dependent variable, age subgroup (Z75 or o75 years) as the factor, and
baseline HbA1c as the covariate. HbA1c ¼ glycated hemoglobin; HOMA-2%β ¼ homeostasis model
assessment-2%β; IRR ¼ incidence rate ratio.
S. Perl et al.dysfunction. The physiologic response to hypoglycemia
includes a combination of reduced insulin secretion and
increased glucagon secretion.25 In the absence of aHypoglycemia event ratea
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Clinical Therapeuticsautonomic nervous system, and the net effect of the
counter-regulatory response is an increase in plasma
glucose concentrations. The autonomic response to re-
peated hypoglycemia is reduced in patients with advanced
T2D.26 Hypoglycemia-associated autonomic failure, a
reduced autonomic counter-regulatory response to hypo-
glycemia following a recent episode of hypoglycemia,27
was demonstrated in patients with T2D receiving insulin
or oral antidiabetes medications after hypoglycemia on 2
consecutive days.26 In these patients, the glucose
threshold for counter-regulatory autonomic hormone
release (epinephrine and norepinephrine) and neurogenic
and neuroglycopenic symptoms were lower, thus increas-
ing the risk for hypoglycemia.26 Further support for a
more robust or intact counter-regulatory response to
hypoglycemia in patients with higher β-cell function was
reported in a study that measured the glucagon response
to hypoglycemia in patients with T2D and moderate β-
cell dysfunction.28 Compared with patients without
diabetes, the glucagon response to hypoglycemia was
reduced by 45% in patients with T2D. Additionally,
insulin secretion decreased more slowly and to a lesser
extent in patients with T2D compared with patients
without diabetes, while secretions of epinephrine,
norepinephrine, and cortisol were not different between
the 2 groups of patients.
In theory, patients with higher baseline β-cell
function may also have better α-cell function. The
coordinated signaling between β cells to decrease
insulin and α cells to increase glucagon secretion
during hypoglycemia may be altered in diabetes.25
Restoration of the reduction in insulin secretion
during hypoglycemia in patients with advanced β-cell
failure resulted in a 2-fold increase from baseline in
glucagon secretion.29 Thus, reciprocal signaling
between insulin and glucagon depends on the health
of both α and β cells.
In the present study, the percentage of patients
who achieved HbA1c o7.0% at week 52 without
severe or conﬁrmed hypoglycemia was higher in
patients with a HOMA-2%β 4median than in
patients with HOMA-2%β rmedian, regardless of
treatment. Additionally, patients with low baseline
β-cell function receiving glimepiride plus metformin
had an increased risk for hypoglycemia compared
with patients who had higher baseline β-cell func-
tion. Although a similar numeric trend was observed
with the addition of saxagliptin to metformin, the
overall hypoglycemia event rate was much lower8with saxagliptin than with glimepiride in patients
with lower and higher baseline β-cell function.
Sulfonylureas such as glimepiride are well known
to increase hypoglycemia risk, and studies have
observed more β-cell dysfunction in individuals tak-
ing sulfonylureas. For example, a retrospective anal-
ysis of year-4 data from the BetaDecline (Factors
Associated with Beta-Cell Dysfunction in Type 2
Diabetes) study,30 a prospective, longitudinal,
multicenter study involving 507 patients with T2D
on stable oral antidiabetes medications or diet
therapy, found that patients with β-cell dysfunction
were 4-fold more likely to be using a sulfonylurea
or a meglitinide than other antidiabetes medications,
including metformin, thiazolidinediones, and acar-
bose. Similar ﬁndings were observed in ADOPT
(A Diabetes Outcome Progression Trial),31 which
examined the durability of monotherapy with
glyburide, metformin, and rosiglitazone in 4360
patients recently diagnosed with T2D who were
treatment naive.31 The cumulative percentages of
treatment failure at 5 years were 34% with
glyburide, 21% with metformin, and 15% with
rosiglitazone. After Z3.3 years, the annual rate of
β-cell decline, as assessed by HOMA, was greatest in
individuals who were taking glyburide (–6.1%),
followed by metformin (–3.1%), and rosiglitazone
(–2.0%).31 Furthermore, patients taking glyburide
had a signiﬁcantly greater prevalence of patient-
reported hypoglycemia events (38.7%) compared
with that in patients taking rosiglitazone (9.8%),
and a numerically greater prevalence of events
compared with patients taking metformin (11.6%).
These studies highlight the different effects among
antidiabetes medications on β-cell function and
maintenance of glycemic homeostasis.
Saxagliptin has been associated with positive
effects on pancreatic β-cell function. By increasing
glucose-dependent insulin secretion, saxagliptin im-
proves glycemic control, reducing fasting32–34 and
postprandial32,34 glucose concentrations and im-
proving glucose disposal.35 Additionally,
improvements in pancreatic β-cell function and a
decrease in postprandial glucagon have been ob-
served.32,35,36 In a subanalysis of the Saxagliptin
Assessment of Vascular Outcomes Recorded in Pa-
tients with Diabetes Mellitus-Thrombolysis in My-
ocardial Infarction trial in 16,492 patients with a
history of T2D and cardiovascular disease, β-cellVolume ] Number ]
S. Perl et al.function was increased in individuals receiving sax-
agliptin and decreased in patients receiving placebo
at 2 years.37,38 Furthermore, results from studies
using animal models of diabetes suggest that sax-
agliptin may protect and/or enhance pancreatic β-cell
function.39–44
There was a signiﬁcant association between lower
β-cell function at baseline and increased prevalence of
hypoglycemia in patients aged 60–o75 years andZ75
years in the current study, with a greater association
noted in thoseZ75 years. These ﬁndings are especially
relevant given that hypoglycemia morbidity is more
prevalent in older patients with T2D3 and that the
frailty of these patients is associated with devastating
complications.5–7,9 The management of diabetes in
older individuals is challenging because of age-related
physiologic, physical, and cognitive changes.
The lower rate of hypoglycemia in patients aged
Z75 years observed in this study was somewhat
surprising. Given that aging in the absence of a
diagnosis of diabetes is associated with altered
glucose-insulin dynamics,45 a ﬁnding that has also
been observed in older, frail patients with T2D,46 one
would have expected a higher hypoglycemia rate in
patients agedZ75 years. However, a greater percentage
of individuals in this post hoc analysis were aged
o75 years; therefore, the smaller sample size of
patients agedZ75 years may have affected this ﬁnding.
We designated patients with HOMA-2%β values at
or below and above the median as having low and
high β-cell function, respectively. One should bear in
mind that this designation of low or high β-cell
function as assessed by the HOMA-2 model reﬂects
insulin secretory capacity (not total insulin
content),17,43 overall viability,41,42,44 or morphology
of β cells.43 Additionally, the HOMA-2 model assesses
insulin sensitivity and β-cell function in the basal
state and does not provide information about the
stimulated state.17 Another potential limitation is the
post hoc nature of this study.
Although not a limitation, it is important to address
the statistical methodology used herein as well as the
data presented. Hypoglycemia IRRs were estimated using
a Poisson regression model that included hypoglycemia
events during the treatment period as the dependent
variable, baseline HOMA-2%β as the factor, and base-
line HbA1c as the covariate. The model adjusted for
baseline HbA1c to avoid potential confounding effects
from differences between treatment groups. Additionally,] 2016we have provided crude event rates, the number of events
per total exposure patient-years, to provide the reader
with an estimate of the total number of hypoglycemia
events over the study period. In our opinion, the model-
adjusted IRR is a better estimation compared with crude
event rate ratio because the hypoglycemia prevalence rate
was adjusted by baseline HbA1c.
In light of our observations, which show a higher
hypoglycemia event rate in patients with low baseline
β-cell function who received glimepiride, judicious use
of sulfonylureas is warranted in individuals who have
poor β-cell function. Comorbid conditions such as
hypertension and hyperlipidemia47 and longer
duration of diabetes47,48 have been associated with
poor β-cell function and are likely to coexist in older
patients with T2D. When selecting an oral antidia-
betes agent for use in the elderly, the assessment of
β-cell function may offer insight on the risk for
hypoglycemia and guide the clinician’s decision-
making process. Saxagliptin has demonstrated efﬁcacy
and tolerability in patients with T2D aged Z65 years
when used as monotherapy or add-on therapy,12–15
suggesting that it is an appropriate treatment option
for many older patients.ACKNOWLEDGMENTS
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